source
- Kyverna reports positive one-year CAR-T results for rare stiff person syndrome, supporting FDA filingKyverna Therapeutics announced that its CAR-T therapy for stiff person syndrome showed positive results after one year of treatment. The trial involved patients with the rare autoimmune disorder,…
- Elevar Therapeutics receives FDA approval for Lyrfigtu as second-line treatment for bile duct cancerThe U.S. Food and Drug Administration has approved Elevar Therapeutics' drug Lyrfigtu as a second‑line option for patients with bile duct cancer who meet specific criteria. Bile duct cancer is dia…